Reviva Pharmaceuticals Holdings Inc. Cash Flow Conversion Efficiency
Reviva Pharmaceuticals Holdings Inc. cash flow conversion efficiency. Based on the latest financial reports, Reviva Pharmaceuticals Holdings Inc. (RVPH) has a cash flow conversion efficiency ratio of -0.389x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.92 Trillion) by net assets ($15.21 Trillion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Reviva Pharmaceuticals Holdings Inc. (2018–2025)
Cash flow conversion efficiency of Reviva Pharmaceuticals Holdings Inc. from 2018 to 2025. This chart illustrates how Reviva Pharmaceuticals Holdings Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View Reviva Pharmaceuticals Holdings Inc. (RVPH) share price today for real-time trading data and today's change.
Reviva Pharmaceuticals Holdings Inc. Cash Flow Conversion Ratio Explained
Reviva Pharmaceuticals Holdings Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Reviva Pharmaceuticals Holdings Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Reviva Pharmaceuticals Holdings Inc. ranked by their cash flow conversion efficiency. Also see Reviva Pharmaceuticals Holdings Inc. (RVPH) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GIGLIO.COM S.P.A. O.N.
F:5JR0
|
N/A |
|
Identi Healthcare Ltd
TA:IDNT
|
-0.437x |
|
Argentina Lithium & Energy Corp
V:LIT
|
-0.020x |
|
Citra Nusa Holdings Bhd
KLSE:5104
|
0.019x |
|
Maschinenfabrik HEID AG
VI:HED
|
N/A |
|
J-Long Group Limited
NASDAQ:JL
|
-0.351x |
|
Encres Dubuit SA
PA:ALDUB
|
0.056x |
|
Rossi Residencial S.A
SA:RSID3
|
-0.033x |
Annual Cash Flow Conversion Efficiency for Reviva Pharmaceuticals Holdings Inc. (2018–2025)
The table below shows the annual cash flow conversion efficiency of Reviva Pharmaceuticals Holdings Inc. from 2018 to 2025. Review RVPH free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $8.65 Million | $-24.59 Million | -2.844x | +93.11% |
| 2024-12-31 | $812.57K | $-33.54 Million | -41.281x | -733.47% |
| 2023-12-31 | $5.72 Million | $-28.32 Million | -4.953x | -119.28% |
| 2022-12-31 | $8.39 Million | $-18.96 Million | -2.259x | -507.36% |
| 2021-12-31 | $28.69 Million | $-10.67 Million | -0.372x | +50.01% |
| 2020-12-31 | $5.47 Million | $-4.07 Million | -0.744x | -2419.97% |
| 2019-12-31 | $-6.81 Million | $-218.44K | 0.032x | +277.08% |
| 2018-12-31 | $59.16 Million | $-1.07 Million | -0.018x | -- |
About Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, s… Read more